Tezepelumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tezepelumab: From an Unspecified Original Indication to Diabetic Cataract
One-Sentence Summary
Tezepelumab (marketed in Singapore as TEZSPIRE) is an injectable anti-TSLP monoclonal antibody. The approved indication text is not available in the data compiled for this report. The TxGNN model predicts it may be effective for diabetic cataract, with a high score (98.4%) but no clinical trials and no publications supporting this direction. The prediction is based on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the registration data |
| Predicted New Indication | Diabetic cataract |
| TxGNN Prediction Score | 98.40% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on general knowledge, tezepelumab is an anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody. It blocks epithelial-alarmin signalling that drives type 2 and other inflammatory responses.
The link to diabetic cataract is indirect and speculative. Lens damage in diabetes is driven mainly by polyol pathway flux, oxidative stress and glycation. TSLP has no established role in these processes. The high TxGNN score reflects a network-based prediction only, and no experimental or clinical data support it.
The same pattern appears across the other predicted indications, which are mostly cataract subtypes (craniostenosis, mature, immature, tetanic, cortical, nuclear senile and senile cataract, and type 2 diabetes-associated cataract). These share nearly identical scores (about 0.982–0.983), which suggests a graph-propagation artefact across related eye conditions. Several of these have clearly unrelated causes, such as genetic or developmental causes, hypocalcaemia, or age-related oxidative damage. Diabetic retinopathy (score 98.1%) is the most biologically plausible of the list because of its inflammatory component, but the established drivers are VEGF and microvascular injury, and the role of TSLP is unproven.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16815P | TEZSPIRE Solution for Injection 210 mg in Pre-filled Syringe | Injection, solution | Not available |
| SIN16817P | TEZSPIRE Solution for Injection 210 mg in Pre-filled Pen | Injection, solution | Not available |
Both authorizations are valid single-ingredient products from Amgen Manufacturing Limited LLC.
Safety Considerations
Please refer to the package insert for safety information.
No drug-drug interaction records were found, and no knowledge-graph contraindicated diseases were identified. This should not be read as evidence of safety, because the package insert data have not yet been obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score. There are no trials or publications, and the mechanistic link between TSLP blockade and lens opacity is weak. The package insert safety data are also missing, so safety screening cannot proceed.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website, and the approved indication text for the two registrations
- Mechanism of action data from DrugBank
- Preclinical evidence on TSLP expression or signalling in lens epithelium or in diabetic eye tissue
- A literature and trial search specific to tezepelumab and diabetic eye disease
- Consideration of diabetic retinopathy as a more plausible alternative hypothesis, and an assessment of whether a systemic biologic suits an ocular indication (route and delivery compatibility has not yet been evaluated)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.